Correlation between Interleukin-6 with D-dimer and C-reactive protein Levels in Patients with Confirmed COVID-19 Severe Criteria
DOI:
https://doi.org/10.24853/mmj.5.2.69-75Keywords:
COVID-19 severe criteria, c-reactive protein, d-dimer, interleukin-6Abstract
Background: In Coronavirus Disease 2019 (COVID-19) severe criteria, cytokine storm conditions are often found, and there will be an increase in Interleukin-6 as a cytokine and CRP as an acute phase protein induced by IL-6. In COVID-19 patients with severe criteria, coagulation disorders can also be found, characterized by an increase in the D-dimer value. Purpose: To determine the correlation between IL-6, D-dimer, and CRP levels in patients with confirmed COVID-19 severe criteria at Bunda Margonda General Hospital in 2021. Methods: This research was an analytical observation study with a cross-sectional approach, using secondary data from medical records of patients with confirmed COVID-19 severe criteria at Bunda Margonda General Hospital in 2021. Results: The number of patients with confirmed COVID-19 severe criteria was primarily male (59%), aged 46-55 years (33%), with degree of severity with severe criteria in 100 patients, increased IL-6 (91%), increased D-dimer levels (90%), increased CRP levels (95%). There was a correlation between increased IL-6 with D-dimer levels (p-value 0,005) and a correlation between increased IL-6 with CRP levels (p-value of 0,000). A simultaneous and significant relationship was found between IL-6, D-dimer, and CRP levels in severe COVID-19 criteria. COVID-19 patients with severe criteria were more commonly found in males in the 46-55-year age group with increased IL-6, D-dimer, and CRP values. Conclusion: There was a correlation between increased IL-6 and D-dimer and CRP levels in COVID-19 patients with severe criteria at Bunda Margonda General Hospital in 2021.References
Susilo A, Rumende CM, Pitoyo CW, Santoso WD, Yulianti M, Herikurniawan H, et al. Coronavirus Disease 2019: Tinjauan Literatur Terkini. J Penyakit Dalam Indones. 2020 Apr;7(1):45–67.
WHO. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. 2022.
Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433.
Sabaka P, Koščálová A, Straka I, Hodosy J, Lipták R, Kmotorková B, et al. Role of interleukin 6 as a predictive factor for a severe course of Covid-19: retrospective data analysis of patients from a long-term care facility during Covid-19 outbreak. BMC Infect Dis. 2021;21(1):1–9.
Liu T, Zhang J, Yang Y, Ma H, Li Z, Zhang J, et al. The role of interleukin-6 in monitoring severe case of coronavirus disease 2019. EMBO Mol Med. 2020 Jul;12(7).
Wardika IK, Sikesa IGPH. Pengukuran Interleukin-6 (IL-6), C-Reactive Protein (CRP) dan D-Dimer sebagai prediktor prognosis pada pasien COVID-19 gejala berat: sebuah tinjauan pustaka. Intisari Sains Medis. 2021;12(3):901.
Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. 2020;
Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z. Plasma CRP level is positively associated with the severity of COVID-19. Ann Clin Microbiol Antimicrob. 2020;19(1).
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr;382(18):1708–20.
Biswas M, Rahaman S, Kumar Biswas T, Haque Z, Ibrahim B. Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. Meta-Analysis Intervirology. 2019;64:36–47.
Tursina A. COVID-19 dan Lansia. Kopidpedia Bunga Rampai Artikel Penyakit Virus Corona. 2020;143–51.
Biswas M, Rahaman S, Biswas TK, Haque Z, Ibrahim B. Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. Intervirology. Switzerland; 2020. p. 1–12.
Putri, Putra, Mariko. Hubungan Usia, Jenis Kelamin dan Gejala Dengan Kejadian COVID-19 di Sumatera Barat. Hub Usia, Jenis Kelamin Dan Gejala Dengan Kejadian COVID-19 di Sumatera barat. 2021;44(2):104–11.
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell [Internet]. 2020/03/05. 2020 Apr 16;181(2):271-280.e8. Available from: https://pubmed.ncbi.nlm.nih.gov/32142651
Sugitha KSL. COVID-19: Respon imunologis, ketahanan pada permukaaan benda dan pilihan terapi klinis. Intisari Sains Medis. 2020;11(2):791.
Yin J-X, Agbana YL, Sun Z-S, Fei S-W, Zhao H-Q, Zhou X-N, et al. Increased interleukin-6 is associated with long COVID-19: a systematic review and meta-analysis. Infect Dis Poverty [Internet]. 2023;12(1):43. Available from: https://doi.org/10.1186/ s40249-023-01086-z
Nikkhoo B, Mohammadi M, Hasani S, Sigari N, Borhani A, Ramezani C, et al. Elevated interleukin (IL)-6 as a predictor of disease severity among Covid-19 patients: a prospective cohort study. BMC Infect Dis. 2023 May;23(1):311.
Li J, Liu Z, Wu G, Yi M, Chen Y, Li K, et al. D-Dimer as a Prognostic Indicator in Critically Ill Patients Hospitalized With COVID-19 in Leishenshan Hospital, Wuhan, China. Front Pharmacol. 2020 Dec;11.
Uciechowski P, Dempke WCM. Interleukin-6: A Masterplayer in the Cytokine Network. Oncology. 2020;98(3):131–7.
Moreno G, Carbonell R, Bodí M, Rodríguez A. Systematic review of the prognostic utility of D-dimer, disseminated intravascular coagulation, and anticoagulant therapy in COVID-19 critically ill patients. Med Intensiva. 2021 Jan;45(1):42–55.
Downloads
Published
Issue
Section
License
Authors who publish in the Muhammadiyah Medical Journal agree to the following terms:
- Authors retain copyright and grant Muhammadiyah Medical Journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Licence that allows others to adapt (remix, transform, and build) upon the work non-commercially with an acknowledgement of the work's authorship and initial publication in Muhammadiyah Medical Journal.
- Authors are permitted to share (copy and redistribute) the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in Muhammadiyah Medical Journal.
